NCT00258934View on ClinicalTrials.gov

Immunogenicity Study of the Influenza Vaccine in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

978

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

September 30, 2008

Conditions
Orthomyxoviridae InfectionsInfluenza
Interventions
BIOLOGICAL

Inactivated, split-virion influenza vaccine

0.1 mL single annual dose

BIOLOGICAL

Inactivated, split-virion, influenza virus

0.5 mL single annual dose

Trial Locations (4)

Unknown

Antwerp

Ghent

Hamburg

Allschwil

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00258934 - Immunogenicity Study of the Influenza Vaccine in Adults | Biotech Hunter | Biotech Hunter